Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 21,100 shares, a decline of 86.8% from the October 15th total of 159,900 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average trading volume of 15,490,000 shares, the short-interest ratio is presently 0.0 days.
Bluejay Diagnostics Price Performance
Shares of BJDX stock traded down $0.01 during trading hours on Wednesday, hitting $0.10. The stock had a trading volume of 4,406,366 shares, compared to its average volume of 5,153,225. The stock’s 50-day moving average price is $0.12 and its two-hundred day moving average price is $1.39. Bluejay Diagnostics has a one year low of $0.07 and a one year high of $31.28. The stock has a market capitalization of $1.70 million, a price-to-earnings ratio of 0.00 and a beta of 0.73.
Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($5.12) EPS for the quarter.
Hedge Funds Weigh In On Bluejay Diagnostics
About Bluejay Diagnostics
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
See Also
- Five stocks we like better than Bluejay Diagnostics
- The How And Why of Investing in Oil Stocks
- Rocket Lab is the Right Stock for the Right Time
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Using the MarketBeat Dividend Tax Calculator
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.